Helocyte

Executive Summary

Helocyte is a private biotechnology company founded in 2015 and based in Foster City, California, specializing in novel immunotherapies and vaccines targeting cytomegalovirus (CMV) and other infectious diseases. The company operates in the high-growth cell and gene therapy sector, with a focus on addressing the significant unmet medical need in CMV, which can cause severe complications in immunocompromised patients and congenital infections. Helocyte’s lead programs are currently in Phase 1 clinical development, leveraging proprietary platforms designed to elicit robust T-cell responses against CMV antigens. The company’s approach aims to provide a therapeutic and prophylactic solution, differentiating from standard antiviral therapies by harnessing the immune system to achieve durable protection. With a private status and limited public disclosures, Helocyte has maintained a low profile, but its work aligns with the expanding landscape of cell-based immunotherapies for infectious diseases. The company’s continued progress in early-stage trials and potential for strategic partnerships position it as a emerging player in the CMV space, though it faces competition from larger biopharma and academic institutions pursuing similar targets.

Upcoming Catalysts (preview)

• H2 2026Phase 1/2 clinical data readout for lead CMV immunotherapy candidate60% success
• 2026Partnership or licensing deal for CMV vaccine or platform technology50% success
• Q1 2027IND submission for a new infectious disease indication beyond CMV70% success